Zevra Therapeutics Inc (ZVRA) Stock Price, Quote & News

Company Profile

Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 1/2 clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug pro...

Industry: Biotechnology

Sector: Healthcare

Phone: 321 939 3416

Website: zevra.com

Address:

1180 Celebration Boulevard, Suite 103, Celebration, United States

MandoTrades Nov. 16 at 11:30 PM

$ZVRA The institutional ownership keeps going up... including @Rodzilla01 and some other big retail holders, the float is over 80% tied up and growing. But keep penny flipping in your mom's basement!

0 · Reply

HedgeAlerts Nov. 16 at 11:08 PM

Hedge Alert Live - Protect Your Portfolio Contract: $ZVRA $8.00 Put · NOV 21, 2025 Exp Entry Price: $0.05 - $0.05 Exit Price Target: $0.09 Profit Margin: +81% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

HuntingHighAndLow Nov. 16 at 7:04 PM

$ZVRA Given that IntraBio's 12-week crossover study wasn't designed to measure disease progress, but rather their drug’s ability to quickly improve neurological symptoms, the results then could only hint at the potential for slowing disease progress. In the extension phase, with the 5DNPCCSS defined as the primary outcome measure at 12 and 18 months, Aqneursa demonstrated stronger scores than Miplyffa+Miglustat in slowing disease progress. This must be why payers prefer Aqneursa. Wayn, you need a jingle: Less Efficacy for More Money— Mi…PLYF-fa!

1 · Reply

KemPharm_rocks Nov. 16 at 5:06 PM

$ZVRA OPENING A NEW DISCUSSION THREAD: It is high time we Stocktwits peeps focus on a less-discussed, though no less critical topic. As of ending Q3 (September 30th), Miplyffa was sitting at 66% insurance formulary coverage. Why is that number so critical to these analysts who always ask about it, every quarter, without fail? Simple answer: Zevra receives substantially more net revenue from insurance companies for Miplyffa patients on formulary, than through a compassionate care program. So yeah, of course the number one way for Zevra to up its quarterly revenue is to add NEW Miplyffa scripts. However, the number two way, is for Zevra to continue increasing it’s insurance formulary coverage.

2 · Reply

EthanStawk Nov. 16 at 4:43 PM

$ZVRA

0 · Reply

EthanStawk Nov. 16 at 4:43 PM

$ZVRA Now that's what I'm talking about. We got some GRIT!

0 · Reply

KemPharm_rocks Nov. 16 at 2:38 PM

$ZVRA THE ONLY NUMBER YOU NEED TO KNOW:

2 · Reply

MoneyGroupLLC Nov. 16 at 11:26 AM

Enter: $ZVRA Calls Strike Price: $10 Expiry Date: DEC 19 2025 Buy in Price: $0.60 - $0.70 Sell Price: $1.24 Profit : +107% (Turn every $1 into $2.07) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us

0 · Reply

LiquidThetaOptions Nov. 16 at 11:18 AM

💎 LiquidTheta® Live Actionable Trade Asset: $ZVRA Contracts: $ZVRA December 18, 2026 $10 Calls Scale in: $2.52- $3.08 Scale out: $9.80-$16.80 Profit Potential : 143% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

HedgeAlerts Nov. 15 at 11:11 PM

0 · Reply

Zevra Therapeutics, Inc. (ZVRA) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 11 days ago

Zevra Reports Third Quarter 2025 Financial Results and Corporate Update

Oct 29, 2025, 7:30 AM EDT - 18 days ago

Zevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference

Oct 27, 2025, 7:30 AM EDT - 20 days ago

Zevra Therapeutics Announces Details for Q3 2025 Financial Results Call

Oct 6, 2025, 5:51 PM EDT - 5 weeks ago

Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Sep 18, 2025, 7:30 AM EDT - 2 months ago

Zevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA® (arimoclomol) and OLPRUVA® (sodium phenylbutyrate)

Sep 4, 2025, 7:30 AM EDT - 2 months ago

Zevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA® (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)

Aug 28, 2025, 7:30 AM EDT - 2 months ago

Zevra Therapeutics Announces Multiple Datasets on MIPLYFFA® (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)

Aug 26, 2025, 7:30 AM EDT - 2 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences in September

Aug 12, 2025, 8:43 PM EDT - 3 months ago

Zevra Therapeutics, Inc. (ZVRA) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:05 PM EDT - 3 months ago

Zevra Reports Second Quarter 2025 Financial Results and Corporate Update

Aug 4, 2025, 7:30 AM EDT - 3 months ago

Zevra Therapeutics Announces Details for Q2 2025 Financial Results Call

Jul 28, 2025, 6:00 AM EDT - 4 months ago

Zevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C

Jul 18, 2025, 7:30 AM EDT - 4 months ago

Zevra Therapeutics Announces MIPLYFFA® and OLPRUVA® Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)

Jul 16, 2025, 7:30 AM EDT - 4 months ago

Zevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism

May 29, 2025, 4:35 PM EDT - 6 months ago

Zevra Announces Final Results of 2025 Annual Meeting of Stockholders

May 21, 2025, 7:30 AM EDT - 6 months ago

All Three Leading Proxy Advisory Firms – ISS, Glass Lewis, and Egan-Jones – Recommend Zevra Stockholders Vote FOR the Company's Director Nominees

May 13, 2025, 10:45 PM EDT - 6 months ago

Zevra Therapeutics, Inc. (ZVRA) Q1 2025 Earnings Call Transcript

May 6, 2025, 7:30 AM EDT - 6 months ago

Zevra Therapeutics Announces Details for Q1 2025 Financial Results Call

Apr 17, 2025, 7:30 AM EDT - 7 months ago

Zevra Announces Publication of MIPLYFFA® Mechanism of Action Manuscript in Molecular Genetics and Metabolism

Apr 7, 2025, 7:30 AM EDT - 7 months ago

Zevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million

Mar 31, 2025, 4:12 PM EDT - 8 months ago

Zevra Therapeutics Files Preliminary Proxy

Mar 11, 2025, 8:16 PM EDT - 8 months ago

Zevra Therapeutics, Inc. (ZVRA) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 4:05 PM EDT - 8 months ago

Zevra Reports Full Year 2024 and Fourth Quarter Financial Results

Feb 28, 2025, 7:30 AM EST - 9 months ago

Zevra Launches New Disease State Awareness Campaign, ‘Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C

Feb 27, 2025, 7:30 AM EST - 9 months ago

Zevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million

Feb 26, 2025, 9:46 AM EST - 9 months ago

Zevra to Report 2024 Fourth Quarter and Full Year Financial Results

Feb 24, 2025, 4:02 PM EST - 9 months ago

Zevra to Participate at Upcoming Investor Conferences

Jan 30, 2025, 7:30 AM EST - 10 months ago

Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™

Jan 29, 2025, 4:05 PM EST - 10 months ago

Zevra Therapeutics to Participate at Upcoming Investor Conferences

Jan 8, 2025, 11:13 AM EST - 11 months ago

Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the market

AMGN BBIO BMY IOVA LLY MDGL MRK

Dec 17, 2024, 7:30 AM EST - 11 months ago

Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

Dec 6, 2024, 5:00 PM EST - 1 year ago

Zevra Therapeutics Announces Organizational Changes

Nov 21, 2024, 4:51 PM EST - 1 year ago

Zevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA™ (arimoclomol) for Treatment of Niemann-Pick Disease Type C

Nov 13, 2024, 7:12 AM EST - 1 year ago

Zevra Therapeutics, Inc. (ZVRA) Q3 2024 Earnings Call Transcript

Nov 11, 2024, 4:36 PM EST - 1 year ago

Zevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting

Nov 6, 2024, 7:30 AM EST - 1 year ago

Zevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13

Oct 31, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC

Sep 24, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics to Present Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at Sleep Europe 2024

Sep 20, 2024, 12:08 PM EDT - 1 year ago

Zevra Therapeutics' MIPLYFFA™ (arimoclomol) Receives U.S. FDA Approval as Treatment for Niemann-Pick Disease Type C

Sep 20, 2024, 10:14 AM EDT - 1 year ago

US FDA approves Zevra's genetic disorder treatment

Sep 6, 2024, 8:30 AM EDT - 1 year ago

Zevra Therapeutics Presented New Data for Arimoclomol and OLPRUVA® (Sodium Phenylbutyrate) at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium

Aug 13, 2024, 9:45 PM EDT - 1 year ago

Zevra Therapeutics, Inc. (ZVRA) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 12:00 AM EDT - 1 year ago

Zevra Therapeutics Announces Pricing of Underwritten Offering of Common Stock

Aug 8, 2024, 4:01 PM EDT - 1 year ago

Zevra Therapeutics Announces Proposed Public Offering of Common Stock

Aug 7, 2024, 9:34 AM EDT - 1 year ago

Zevra Therapeutics to Present at Canaccord Genuity's 44th Annual Growth Conference

Aug 2, 2024, 5:50 PM EDT - 1 year ago

FDA Advisory Committee Votes Favorably that the Data Support Arimoclomol as Effective Treatment for Patients with Niemann-Pick Disease Type C

Jul 30, 2024, 8:38 AM EDT - 1 year ago

Zevra Therapeutics to Report Second Quarter 2024 Financial Results

Jun 25, 2024, 7:30 AM EDT - 1 year ago

Zevra Therapeutics Expands Executive Leadership Team

MandoTrades Nov. 16 at 11:30 PM

$ZVRA The institutional ownership keeps going up... including @Rodzilla01 and some other big retail holders, the float is over 80% tied up and growing. But keep penny flipping in your mom's basement!

0 · Reply

HedgeAlerts Nov. 16 at 11:08 PM

0 · Reply

HuntingHighAndLow Nov. 16 at 7:04 PM

1 · Reply

KemPharm_rocks Nov. 16 at 5:06 PM

2 · Reply

EthanStawk Nov. 16 at 4:43 PM

$ZVRA

0 · Reply

EthanStawk Nov. 16 at 4:43 PM

$ZVRA Now that's what I'm talking about. We got some GRIT!

0 · Reply

KemPharm_rocks Nov. 16 at 2:38 PM

$ZVRA THE ONLY NUMBER YOU NEED TO KNOW:

2 · Reply

MoneyGroupLLC Nov. 16 at 11:26 AM

0 · Reply

LiquidThetaOptions Nov. 16 at 11:18 AM

0 · Reply

HedgeAlerts Nov. 15 at 11:11 PM

0 · Reply

WaynD01 Nov. 15 at 10:01 PM

$ZVRA As the FDA and US physicians finds EMA also sees Aqneursa(IntraBio) is just a symptom reliever

0 · Reply

WaynD01 Nov. 15 at 9:56 PM

$ZVRA So Highandlow has publicly come forward to proclaim positively on Miplyffa over IntraBio drug. Also you must be noticing that ZVRA’s short interest has been coming down continuously.. Any way this is a good news for MIPLYFFA’s EU penetration, indeed…

0 · Reply

ZVRA100 Nov. 15 at 4:45 PM

$ZVRA i think what’s the most interesting is goldman sachs continuing to double their holdings every quarter. Not to forget, they were one of the names dropped as the facilitator for the bidding process by zakstrader cafe.

1 · Reply

HuntingHighAndLow Nov. 15 at 4:26 PM

$ZVRA @gc358 11/14/25 ZVRA “As we wait the 150 days for EMA decision, the EMA today gave a positive decision on Aqnuersa by IntraBio. We seem late to the party in Europe. Hell it's only a 6-month head start over us.” Hell, Zevra gave up a 3-month head start over IntraBio in the U.S. thanks to Z’s bungled resub of the arimoc NDA, but the news yesterday wants filling in. EMA gave thumbs up on Aqneursa back on 7/25/25. IntraBio requested a re-examination. Reasons for the request are not shared prior to the re-exam; I thought it might be related to the use of miglustat. Now we know that EMA’s positive opinion did not include blessing the drug as a New Active Substance, equivalent to FDA’s New Molecular Entity status. After re-examination, EMA affirmed their original opinion. This has potential negative ramifications for market exclusivity. We know it was important enough for IntraBio to try to secure NAS status as the effort has added almost four months to the EMA review period.

0 · Reply

WaynD01 Nov. 15 at 3:27 PM

$ZVRA Institutional ownership at 78% . Great to see the increasing vote of confidence from the big boys..

0 · Reply

KemPharm_rocks Nov. 15 at 7:14 AM

$ZVRA Go long, or expect to be burned as the MMs play you like a fiddle. Proceed with side-bets at your own financial risk ⚠️. Smell the coffee. The day-to-day pps is an absolute joke, a big magic trick being orchestrated to algorithm, short, & warrant perfection. Strap on your long big-boy pants like the ~80% (and growing) institutional owners.

0 · Reply

MoneyGroupLLC Nov. 15 at 7:08 AM

0 · Reply

Mtoeps Nov. 15 at 5:46 AM

Got $NVO $ASPN $JD $GRAB $ZVRA

0 · Reply

Boflex2201 Nov. 15 at 12:30 AM

$ZVRA One year ago I posted that we just hit 42% institutional ownership. Now we’re over 70%. If nothing else, management is good at that.

1 · Reply

RodRosenstein Nov. 14 at 11:40 PM

$ZVRA @YANEZ Dogstolers or no????? Total dogstolers

1 · Reply

gc358 Nov. 14 at 11:13 PM

$ZVRA As we wait the 150 days for EMA decision, the EMA today gave a positive decision on Aqnuersa by IntraBio. We seem late to the party in Europe. Hell it's only a 6-month head start over us. SMH

2 · Reply

intowits Nov. 14 at 9:29 PM

$ZVRA It looks like "Hello 8's" won out.

0 · Reply

Market Cap	499.93M
Revenue (ttm)	23.61M
Net Income (ttm)	-105.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-446.89%
Debt to Equity Ratio	0.46

Volume	1,767,300
Avg Vol	2,053,456
Day's Range	N/A - N/A
Shares Out	56.30M
Stochastic %K	18%
Beta	1.52
Analysts	Strong Sell
Price Target	$22.86